• John G Armstrong, Charles M Gillham, Mary T Dunne, David A Fitzpatrick, Marie A Finn, Mairín E Cannon, Judy C Taylor, Carmel M O'Shea, Steven J Buckney, and Pierre G Thirion.
• Department of Radiation Oncology, St. Luke's Hospital, Dublin, Ireland.
• Int. J. Radiat. Oncol. Biol. Phys. 2011 Sep 1; 81 (1): 35-45.

PurposeTo examine the long-term outcomes of a randomized trial comparing short (4 months; Arm 1) and long (8 months; Arm 2) neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.Methods And MaterialsBetween 1997 and 2001, 276 patients were enrolled and the data from 261 were analyzed. The stratification risk factors were prostate-specific antigen level >20 ng/mL, Gleason score≥7, and Stage T3 or more. The intermediate-risk stratum had one factor and the high-risk stratum had two or more. Staging was done from the bone scan and computed tomography findings. The primary endpoint was biochemical failure-free survival.ResultsThe median follow-up was 102 months. The overall survival, biochemical failure-free survival. and prostate cancer-specific survival did not differ significantly between the two treatment arms, overall or at 5 years. The cumulative probability of overall survival at 5 years was 90% (range, 87-92%) in Arm 1 and 83% (range, 80-86%) in Arm 2. The biochemical failure-free survival rate at 5 years was 66% (range, 62-71%) in Arm 1 and 63% (range, 58-67%) in Arm 2.ConclusionNo statistically significant difference was found in biochemical failure-free survival between 4 months and 8 months of neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.Copyright © 2011 Elsevier Inc. All rights reserved.

36 keywords...

hide…